MGM-15, also called dihydro-7-hydroxy mitragynine, and MGM-16 are synthetic 7-OH-related compounds that have been studied for opioid-like activity and are now specifically named in federal regulatory action.
Both substances are connected to 7-hydroxymitragynine, often called 7-OH, the potent kratom-related compound that federal agencies have recently targeted for temporary scheduling. While many people are familiar with kratom leaf or even 7-OH tablets and shots, fewer people understand what MGM-15 and MGM-16 are or why they matter.
The short version is this: MGM-15 and MGM-16 are not the same as natural kratom leaf. They are synthetic 7-OH-related compounds that have been studied for opioid-like activity and are now specifically named in federal regulatory action. In July 2026, the DEA announced Notices of Intent to temporarily schedule certain 7-OH products and related substances, including mitragynine pseudoindoxyl, MGM-15, and MGM-16.
For people using kratom, 7-OH, MGM-15, MGM-16, or other opioid-like products, this can be confusing and frightening. Many of these products have been sold in smoke shops, gas stations, vape shops, and online stores with packaging that makes them look legal, natural, or safe. But legal availability does not guarantee safety, and a changing legal market can increase the risk of withdrawal, panic buying, switching substances, or turning to illicit opioids.
At Brooks Healing Center, we believe people deserve clear information without shame. If you are struggling with 7-OH, kratom extracts, MGM-labeled products, or any opioid-like substance, help is available.
What Are MGM-15 and MGM-16?
MGM-15 and MGM-16 are synthetic derivatives of 7-hydroxymitragynine, the opioid-like alkaloid associated with kratom. HHS and FDA have described MGM-15 and MGM-16 as synthetic derivatives of 7-OH that do not naturally occur in the kratom plant.
That distinction is important. Many people think of kratom as a botanical product. However, concentrated 7-OH products and synthetic 7-OH-related compounds are different from plain kratom leaf. They may be more potent, more unpredictable, and more likely to cause dependence or withdrawal.
MGM-15 and MGM-16 were discussed in scientific research years before they appeared in public health warnings. A 2014 study described MGM-15 and MGM-16 as dual-acting opioid agonists synthesized from 7-hydroxymitragynine for pain-related research. The same study reported that MGM-16 showed higher opioid agonist potency than both 7-OH and MGM-15 in experimental models.
MGM-16 vs. MGM-15: At a Glance
| Category | MGM-15 | MGM-16 |
|---|---|---|
| Drug type | Synthetic 7-OH derivative | Synthetic 7-OH derivative |
| Connection to kratom | Related to 7-OH, not natural kratom leaf | Related to 7-OH, not natural kratom leaf |
| Naturally occurring? | No, according to HHS/FDA descriptions | No, according to HHS/FDA descriptions |
| Opioid activity | Studied as an opioid agonist | Studied as an opioid agonist |
| Potency comparison | Less potent than MGM-16 in published research | Reported to have higher opioid agonist potency than 7-OH and MGM-15 in experimental research |
| Federal status | Named in DEA temporary scheduling action | Named in DEA temporary scheduling action |
| Main concern | Opioid-like effects, dependence, withdrawal, uncertain product contents | Potentially stronger opioid-like effects, dependence, withdrawal, uncertain product contents |
Is MGM-16 Stronger Than MGM-15?
Based on available published research, MGM-16 appears to be more potent than MGM-15 in experimental models. The 2014 study on MGM-15 and MGM-16 reported that MGM-16 showed higher opioid agonist potency than 7-hydroxymitragynine and MGM-15 in vitro and in vivo.
However, this does not mean MGM-16 is a safe or approved medication. The research was not a green light for consumer use. These compounds were studied in a controlled research setting, not as unregulated products sold in convenience stores or online.
That difference matters because a labeled product may not provide the same safety controls, purity standards, dose accuracy, or medical supervision that exist in legitimate pharmaceutical research.
Why Are MGM-15 and MGM-16 Being Discussed Now?
MGM-15 and MGM-16 are being discussed because federal agencies have included them in recent action against concentrated and synthetic 7-OH-related substances.
On July 1, 2026, the DEA announced that it was beginning the temporary scheduling process for certain kratom-related substances. According to the DEA, one notice focuses on 7-OH above a specified threshold, while another notice addresses related substances including mitragynine pseudoindoxyl, MGM-15, and MGM-16.
HHS and FDA supported the action, stating that synthetic 7-OH and the three related substances have no currently accepted medical use and a high potential for abuse. HHS also clarified that mitragynine pseudoindoxyl, MGM-15, and MGM-16 do not occur naturally in the kratom plant.
MGM-15, MGM-16, and the “Legal High” Market
The “legal high” market often changes faster than most consumers can follow. When one substance is restricted, new names may appear. Products may be marketed with scientific-sounding labels, abbreviations, colorful packaging, or claims about being natural, safe, or opioid-free.
Florida health officials have warned consumers to watch for products marketed as “7-OH,” “7-OHMZ,” “7-Hydroxy,” “MGM-15,” “MGM-16,” or similar names, especially when sold as gummies, shots, powders, drink mixes, or tablets.
This is one of the biggest dangers for users. A person may think they are buying a kratom product, but the product may contain concentrated 7-OH, synthetic 7-OH derivatives, or other opioid-like compounds. The package may not clearly explain the difference.
Why MGM-16 May Raise Special Concern
MGM-16 may raise special concern because available research suggests it can be more potent than MGM-15 and 7-OH in opioid activity. Potency matters because stronger opioid-like effects can increase the risk of:
- Tolerance
- Dependence
- Withdrawal
- Sedation
- Risky redosing
- Mixing with other substances
- Loss of control over use
- Transitioning to stronger or illicit opioids
This does not mean every person who uses an MGM-labeled product will have the same experience. Dose, frequency, product contents, medical history, and other substance use all matter. But when a compound has opioid-like activity and is sold without reliable medical oversight, the risk becomes much harder to predict.
MGM-15, MGM-16, and Withdrawal
Because MGM-15 and MGM-16 are 7-OH-related opioid agonists, people who use them repeatedly may be at risk for opioid-like withdrawal. There is still limited public clinical information on withdrawal from these specific compounds in humans, but their relationship to 7-OH and opioid receptors raises real concern.
Possible withdrawal symptoms from opioid-like kratom derivatives may include:
- Sweating
- Chills
- Anxiety
- Restlessness
- Insomnia
- Body aches
- Nausea
- Diarrhea
- Runny nose
- Irritability
- Fatigue
- Cravings
- Restless legs
- Depression
Withdrawal can become especially dangerous when people try to manage it alone. Some may use more of the same product, switch to stronger kratom extracts, try tianeptine, mix sedatives, or turn to counterfeit pills or illicit opioids.
Can MGM-15 or MGM-16 Cause Addiction?
MGM-15 and MGM-16 may carry addiction risk because they are opioid-like substances connected to 7-OH. Federal agencies have identified high potential for abuse as part of the reason these substances are being targeted for temporary Schedule I control.
Addiction is not defined by where a product was purchased. A person can become dependent on something bought online, in a smoke shop, or at a gas station. If a substance creates relief, euphoria, or withdrawal avoidance, it can become part of a compulsive cycle.
Signs of a problem may include:
- Using MGM-15, MGM-16, 7-OH, or kratom extracts every day
- Feeling sick, anxious, sweaty, or restless without it
- Needing higher doses over time
- Using to feel normal rather than to feel good
- Hiding use from family or people in recovery
- Spending more money than intended
- Trying to quit but repeatedly returning to use
- Switching products to avoid withdrawal
- Considering illicit opioids when legal products are unavailable
Is MGM-16 Federally Legal?
The federal status of MGM-16 is changing. The DEA named MGM-16 in its July 2026 temporary scheduling action involving 7-OH-related substances. Once a temporary scheduling order takes effect, covered MGM-16 would be placed into Schedule I of the Controlled Substances Act, meaning manufacture, distribution, sale, and possession would be subject to federal controls.
Because scheduling timelines and enforcement dates can change, people should not rely on product labels, retailers, or online sellers for legal guidance.
Is MGM-15 Federally Legal?
MGM-15 is also named in the DEA’s July 2026 temporary scheduling action. Like MGM-16, it is described by HHS and FDA as a synthetic derivative of 7-OH that does not naturally occur in the kratom plant.
Once the DEA’s temporary scheduling order takes effect, covered MGM-15 would be federally controlled under Schedule I. State laws may also restrict these products separately, even before or beyond federal action.
MGM-16 vs. 7-OH
MGM-16 and 7-OH are related, but they are not the same. 7-OH is a kratom-related alkaloid that can occur naturally in trace amounts in the kratom plant, though many commercial 7-OH products contain concentrated or enhanced levels. MGM-16 is a synthetic derivative of 7-OH and is not considered natural kratom leaf.
The DEA’s July 2026 action treats these categories separately. One notice addresses 7-OH above a specified threshold, while another addresses mitragynine pseudoindoxyl, MGM-15, and MGM-16.
Why “Natural” Claims Can Be Misleading
Many kratom-related products are marketed with words like “natural,” “botanical,” “plant-based,” or “wellness.” But those words do not always tell the full story.
A product can be connected to a plant and still be chemically altered, concentrated, or blended with other active compounds. MGM-15 and MGM-16 are examples of why consumers should be careful. They are related to kratom chemistry, but federal agencies describe them as synthetic 7-OH derivatives, not natural kratom leaf.
When a person cannot verify what is in a product, how strong it is, or how it was made, the risk of dependence and withdrawal becomes much harder to manage.
Treatment for MGM-15, MGM-16, 7-OH, and Kratom Dependence
People struggling with MGM-15, MGM-16, 7-OH, kratom extracts, or other opioid-like substances may benefit from professional addiction treatment. Treatment can help address both the physical withdrawal symptoms and the emotional cycle that keeps people returning to use.
Depending on the person’s needs, treatment may involve:
- Medical assessment
- Detox
- Medication-assisted treatment when appropriate
- Residential addiction treatment
- Individual therapy
- Group therapy
- Relapse prevention planning
- Support for anxiety, depression, trauma, or chronic pain
- Aftercare planning
Medication-assisted treatment, or MAT, may be especially important for some people with opioid-like dependence. Instead of relying on products with unclear labeling, inconsistent potency, or changing legal status, MAT can provide a supervised and evidence-based path to stabilize withdrawal and cravings.
How Brooks Healing Center Can Help
Brooks Healing Center provides addiction treatment in Tennessee for people struggling with opioids, kratom products, 7-OH, and other emerging substances. We understand that many people did not set out to develop a substance use problem. Some started with kratom for pain. Some used 7-OH to avoid illicit opioids. Some tried a product because it was legal and available.
Whatever brought you here, you deserve help without shame.
If MGM-15, MGM-16, 7-OH, kratom extracts, or other opioid-like products have become difficult to stop, Brooks Healing Center can help you take the next step toward stability and recovery.
Final Thoughts
MGM-15 and MGM-16 are part of a growing category of kratom-related substances that can look legal, harmless, or natural while still carrying serious risks. MGM-16 may be especially concerning because research has described it as having higher opioid agonist potency than both 7-OH and MGM-15 in experimental settings.
As federal and state laws change, people who are dependent on these products may face withdrawal, fear, and uncertainty. The safest answer is not panic or secrecy. It is support.
If you are using MGM-15, MGM-16, 7-OH, kratom extracts, or any opioid-like product and feel stuck, Brooks Healing Center is here to help.
Sources
Drug Enforcement Administration. (2026, July 1). DEA to temporarily schedule 7-OH and related substances to protect public safety. https://www.dea.gov/press-releases/2026/07/01/dea-temporarily-schedule-7-oh-and-related-substances-protect-public
Florida Department of Health. (2026, June 16). Florida Department of Health issues warning on dangerous opioid-like products sold in stores across Florida. https://www.floridahealth.gov/2026/06/16/florida-department-of-health-issues-warning-on-dangerous-opioid-like-products-sold-in-stores-across-florida/
Matsumoto, K., Horie, S., Takayama, H., Ishikawa, H., Aimi, N., Ponglux, D., Watanabe, K., & Murayama, T. (2014). Orally active opioid μ/δ dual agonist MGM-16, a derivative of 7-hydroxymitragynine, for the treatment of neuropathic pain. Journal of Pharmacology and Experimental Therapeutics, 348(3), 383–392. https://pmc.ncbi.nlm.nih.gov/articles/PMC6067406/
U.S. Department of Health and Human Services. (2026, July 1). HHS, FDA commend DEA action against dangerous enhanced 7-OH products. https://www.hhs.gov/press-room/hhs-fda-support-dea-7-oh-scheduling.html
